KCKonstantinos Chouliaras

Konstantinos Chouliaras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konstantinos Chouliaras has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Robotic versus thoraco-laparoscopic minimally invasive Ivor Lewis esophagectomy, a matched-pair single-center cohort analysis

    by Konstantinos Chouliaras, Kristopher Attwood, Maureen Brady, Hideo Takahashi, June S Peng, Sai Yendamuri, Todd L Demmy, Steven N Hochwald, Moshim Kukar

    Minimally invasive esophagectomy (MIE) is becoming more widespread with a documented improvement in postoperative morbidity based on level I evidence. However, there is a lack of consensus regarding the optimal MIE approach, conventional thoracoscopy/laparoscopy vs robotics as well as the ideal anastomotic technique. All patients who underwent MIE via an Ivor Lewis approach with a side-to-side stapled anastomosis were included. The thoracoscopy-laparoscopy (TL) group was compared to the robotic group with respect to perioperative outcomes using the entire cohorts and after 1:1 propensity score matching. Comparisons were made using the Mann–Whitney U and Fisher’s exact tests. Between July 2013 and November 2020, 72 TL and 67 robotic Ivor Lewis MIE were performed. After comparing the two unadjusted cohorts and 51 propensity matched pairs, there was a decrease in Clavien-Dindo Grade 2 or above complications in the robotic vs TL group (59.7% vs 41.8% [P = 0.042], (62.7% vs 39.2% [P = 0.029]), respectively. In both analyses, there was a reduction in hospital length of stay (median of 8 vs 7 days, P < 0.001) and a trend toward less anastomotic leaks in the robotic group (Unadjusted: 12.5 vs 3% [P = 0.057], Propensity-matched analysis: 13.7% vs 3.9% [P = 0.16]), respectively. A clinically significant decrease in overall morbidity, cardiac complications and hospital length of stay was observed in the robotic Ivor Lewis cohort when compared with the TL group at a high volume MIE program. Side-to-side stapled thoracic anastomoses utilizing a robotic platform provides the best outcomes in this single institution experience.


  • ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms

    by Malcolm H. Squires, Cecilia G. Ethun, Erin E. Donahue, Jennifer H. Benbow, Colin J. Anderson, Megan H. Jagosky, Munsa Manandhar, Joshua C. Patt, Jeffrey S. Kneisl, Jonathan C. Salo, et al.

  • Open Access

    A case from the future of HPB surgical oncology: resection of biliary tract cancer after immunotherapy

    by Vikas Satyananda, Konstantinos Chouliaras, Leonid Cherkassky, Roderich E Schwarz

    Biliary tract cancers (BTCs) have limited response to systemic therapy and poor prognosis. Immunotherapy in BTCs has been investigated in recent years. Here, we report a case of locally advanced, unresectable gallbladder adenocarcinoma that progressed on chemotherapy. The patient was then treated with ipilimumab and nivolumab, which resulted in tumor shrinkage and autoimmune hepatitis, but established technical resectability. He underwent complete resection through extended right hepatectomy with en bloc cholecystectomy bile duct resection, hepatic and portal lymphadenectomy and Roux-Y hepaticojejunostomy reconstruction. The final pathology revealed a pathologic complete response. The scope of operative intervention after immunotherapy is still evolving for BTCs. Establishing resectability in tumors not susceptible to cytotoxic agents but responding to immunotherapy not only facilitates curative intent resection but also enhances the importance of infection prevention through operative stent-free long-term biliary decompression. Immunotherapy may also carry a unique risk profile for post-operative morbidity potential as in this case with autoimmune hepatitis.


  • A multi‐institutional validation study of prognostic nomograms for retroperitoneal sarcoma

    by Malcolm H. Squires, Cecilia G. Ethun, Erin E. Donahue, Jennifer H. Benbow, Colin J. Anderson, Megan H. Jagosky, Jonathan C. Salo, Joshua S. Hill, William Ahrens, Roshan S. Prabhu, et al.

    Background and Objectives: Prognostic nomograms for patients undergoing resection of retroperitoneal sarcoma (RPS) include the Sarculator and Memorial Sloan Kettering (MSK) sarcoma nomograms. We sought to validate the Sarculator and MSK nomograms within a large, modern multi‐institutional cohort of patients with primary RPS undergoing resection.Methods: Patients who underwent resection of primary RPS between 2000 and 2017 across nine high‐volume US institutions were identified. Predicted 7‐year disease‐free (DFS) and overall survival (OS) and 4‐, 8‐, and 12‐year disease‐specific survival (DSS) were calculated from the Sarculator and MSK nomograms, respectively. Nomogram‐predicted survival probabilities were stratified in quintiles and compared in calibration plots to observed survival outcomes assessed by Kaplan–Meier estimates. Discriminative ability of nomograms was quantified by Harrell's concordance index (C‐index).Results: Five hundred and two patients underwent resection of primary RPS. Histologies included leiomyosarcoma (30%), dedifferentiated liposarcoma (23%), and well‐differentiated liposarcoma (15%). Median tumor size was 14.0 cm (interquartile range [IQR], 8.5–21.0 cm). Tumor grade distribution was: Grade 1 (27%), Grade 2 (17%), and Grade 3 (56%). Median DFS was 31.5 months; 7‐year DFS was 29%. Median OS was 93.8 months; 7‐year OS was 51%. C‐indices for 7‐year DFS, and OS by the Sarculator nomogram were 0.65 (95% confidence interval [CI]: 0.62–0.69) and 0.69 (95%CI: 0.65–0.73); plots demonstrated good calibration for predicting 7‐year outcomes. The C‐index for 4‐, 8‐, and 12‐year DSS by the MSK nomogram was 0.71 (95%CI: 0.67–0.75); plots demonstrated similarly good calibration ability.Conclusions: In a diverse, modern validation cohort of patients with resected primary RPS, both Sarculator and MSK nomograms demonstrated good prognostic ability, supporting their ongoing adoption into clinical practice.


  • Reply to: Do surgical margins affect the overall survival in patients with soft tissue sarcomas?

    by Konstantinos Chouliaras, Konstantinos I. Votanopoulos

  • Impact of resection margin on outcomes in high‐grade soft tissue sarcomas of the extremity—A USSC analysis

    by Konstantinos Chouliaras, Nathan Patel, Rebecca Senehi, Cecilia G. Ethun, George Poultsides, Valerie Grignol, Thomas Clark Gamblin, Kevin K. Roggin, Ryan C. Fields, Ralph D'AGostino, et al.

    Background: The optimal margin of resection for high‐grade extremity sarcomas and its impact on survival has long been questioned in the setting of adjuvant radiotherapy. The objective of this study was to investigate the impact of resection status on recurrence and survival.Methods: All patients with primary, nonmetastatic, high‐grade extremity sarcomas that underwent surgical resection from January 2000 to April 2016 in the U.S. Sarcoma Collaborative (USSC) were retrospectively reviewed. Recurrence patterns, recurrence‐free survival (RFS), and overall survival (OS) were examined in multivariate analyses (MVA).Results: A cohort of 959 patients was identified with a median follow‐up of 34.7 months from diagnosis. R0 resection was achieved in 86.7% (831) while R1 resection in 13.3% (128). Locoregional recurrence for R0 and R1 groups occurred in 9.1% (76) versus 14.8% (19; p = .05) while distant recurrence occurred in 24.7% (205) versus 26.6% (34; p = .65), respectively. Median RFS was 171.2 versus 48.5 (p = .01) while median OS was 149.8 versus 71.5 months (p = .02) for the R0 versus R1 group, respectively. On MVA, female gender (hazard ratio [HR] = 0.69, p = .007) and adjuvant radiotherapy (0.7, p = .04) were associated with improved OS, whereas older age (HR = 1.03, p < .001) and tumor size (HR = 1.01, p < .001) were associated with worse OS. R0 resection status was associated with improved locoregional RFS (HR = 0.56, p = .03) but not with distant RFS (HR = 0.84, p = .4) or OS (HR = 0.7, p = .052).Conclusions: In high‐grade extremity sarcomas, tumor size and gender are predictive of OS while R0 resection status is associated with improved locoregional recurrence rate without a significant impact on distant RFS or OS.


  • Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer

    by Konstantinos Chouliaras, Yoshihisa Tokumaru, Mariko Asaoka, Masanori Oshi, Kristopher M. Attwood, Kazuhiro Yoshida, Takashi Ishikawa, Kazuaki Takabe


  • Role of Adjuvant Radiation Therapy for Retroperitoneal Sarcomas: An 8-Institution Study from the US Sarcoma Collaborative

    by Konstantinos Chouliaras, Kenneth Cardona, George A. Poultsides, Valerie P. Grignol, Callisia N. Clarke, Kevin Roggin, Ryan C. Fields, Sharon M. Weber, Emily Johnson, Konstantinos Votanopoulos

  • Role of radiation therapy for retroperitoneal sarcomas: An eight‐institution study from the US Sarcoma Collaborative

    by Konstantinos Chouliaras, Rebecca Senehi, Cecilia G. Ethun, George Poultsides, Valerie Grignol, Callisia N. Clarke, Kevin K. Roggin, Ryan C. Fields, Patrick B. Schwartz, Sean M. Ronnekleiv‐Kelly, et al.

    Background: The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear.Methods: A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded.Results: Total 425 patients were included, 56 in the neoadjuvant radiation group (neo‐RT), 75 in the adjuvant radiation group (adj‐RT), and 294 in the no radiotherapy group (no‐RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj‐RT and 59 neo‐RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence‐free survival (RFS) was 35.9 months (no‐RT) vs 33.5 months (neo‐RT) and 27.2 months (adj‐RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no‐RT) vs 33.9 months (neo‐RT), P = .28 and 19 months (no‐RT) vs 27.2 months (adj‐RT), P = .1.Conclusions: Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.


  • Recurrence patterns after resection of retroperitoneal sarcomas: An eight‐institution study from the US Sarcoma Collaborative

    by Konstantinos Chouliaras, Rebecca Senehi, Cecilia G. Ethun, George Poultsides, Thuy Tran, Valerie Grignol, Thomas Clark Gamblin, Kevin K. Roggin, Jennifer Tseng, Ryan C. Fields, et al.

    Background and Objectives: Resection of primary retroperitoneal sarcomas (RPS) has a high incidence of recurrence. This study aims to identify patterns of recurrence and its impact on overall survival.Methods: Adult patients with primary retroperitoneal soft tissue sarcomas who underwent resection in 2000‐2016 at eight institutions of the US Sarcoma Collaborative were evaluated.Results: Four hundred and ninety‐eight patients were analyzed, with 56.2% (280 of 498) having recurrences. There were 433 recurrences (1‐8) in 280 patients with 126 (25.3%) being locoregional, 82 (16.5%) distant, and 72 (14.5%) both locoregional and distant. Multivariate analyses revealed the following: Patient age P = .0002), tumor grade (P = .02), local recurrence (P = .0003) and distant recurrence (P < .0001) were predictors of disease‐specific survival. The 1‐, 3‐, and 5‐year survival rate for patients who recurred vs not was 89.6% (standard error [SE] 1.9) vs 93.5% (1.8), 66.0% (3.2) vs 88.4% (2.6), and 51.8% (3.6) vs 83.9% (3.3), respectively, P < .0001. Median survival was 5.3 years for the recurrence vs 11.3+ years for the no recurrence group (P < .0001). Median survival from the time of recurrence was 2.5 years.Conclusions: Recurrence after resection of RPS occurs in more than half of patients independently of resection status or perioperative chemotherapy and is equally distributed between locoregional and distant sites. Recurrence is primarily related to tumor biology and is associated with a significant decrease in overall survival.